

## DAFTAR PUSTAKA

- Aldous, S.J., 2013, Cardiac biomarkers in acute myocardial infarction, *Int. J. Cardiol.* 164, 282–294.
- Ali, S., Huber, M., Kollwe, C., Bischoff, S.C., Falk, W., Martin, M.U., 2007, IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells, *Proc. Natl. Acad. Sci. U. S. A.* 104, 18660–18665.
- Allen, J.C., 2011, Sample size calculation for two independent groups: A useful rule of thumb, *Proc. Singapore Healthc.* 20, 138–140.
- Alonso, N., Lupin, J., Barallat, J., de Antonio, M., Domingo, M., Zamora, E., *et al.*, 2016, Impact of diabetes on the predictive value of heart failure biomarkers, *Cardiovasc. Diabetol.* 15, 1–9.
- Andersson, C., Enserro, D., Sullivan, L., Wang, T.J., Januzzi, J.L., Benjamin, E.J., *et al.*, 2016, Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study, *Atherosclerosis* 248, 245–251.
- Arend, W.P., Palmer, G., Gabay, C., 2008, IL-1, IL-18, and IL-33 families of cytokines, *Immunol. Rev.* 223, 20–38.
- Armstrong, P.W., Gershlick, A.H., Goldstein, P., Wilcox, R., Danays, T., Lambert, Y., *et al.*, 2013, Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction, *N. Engl. J. Med.* 368, 1379–1387.
- Baekkevold, E.S., Roussigné, M., Yamanaka, T., Johansen, F.E., Jahnsen, F.L., Amalric, F., *et al.*, 2003, Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules, *Am. J. Pathol.* 163, 69–79.
- Baines, C.P., Molkentin, J.D., 2005, STRESS signaling pathways that modulate cardiac myocyte apoptosis, *J. Mol. Cell. Cardiol.* 38, 47–62.
- Bandara, G., Beaven, M.A., Olivera, A., Gilfillan, A.M., Metcalfe, D.D., 2015, Activated mast cells synthesize and release soluble ST2—a decoy receptor for IL-33, *Eur. J. Immunol.* 45, 3034–3044.
- Barbarash, O., Gruzdeva, O., Uchasova, E., Dyleva, Y., Belik, E., Akbasheva, O., *et al.*, 2016, Prognostic value of soluble ST2 during hospitalization for st-segment elevation myocardial infarction, *Ann. Lab. Med.* 36, 313–319.
- Barksby, H.E., Lea, S.R., Preshaw, P.M., Taylor, J.J., 2007, The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders, *Clin. Exp. Immunol.* 149, 217–225.
- Bartunek, J., Delrue, L., Van Durme, F., Muller, O., Casselman, F., De Wiest, B., *et al.*, 2008, Nonmyocardial Production of ST2 Protein in Human Hypertrophy and

- Failure Is Related to Diastolic Load, *J. Am. Coll. Cardiol.* 52, 2166–2174.
- Bayes-Genis, A., Pascual-Figal, D., Januzzi, J.L., Maisel, A., Casas, T., Valdés, M., *et al.*, 2010, Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure, *Rev. Española Cardiol.* English Ed. 63, 1171–1178.
- Bett, J.H., 1993, LATE assessment of thrombolytic efficacy with alteplase (rt-PA) six-24 hours after onset of acute myocardial infarction, *Aust N Z J Med* 23, 745–748.
- Boersma, E., Maas, A.C., Deckers, J.W., Simoons, M.L., Davie, a P., 1996, Early thrombolytic treatment in acute myocardial infarction, *Lancet* 348, 1312–1313.
- Boisot, S., Beede, J., Isakson, S., Chiu, A., Clopton, P., Januzzi, J., *et al.*, 2008, Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure, *J. Card. Fail.* 14, 732–738.
- Bonnefoy, E., Steg, P.G., Boutitie, F., Dubien, P.Y., Lapostolle, F., Roncalli, J., *et al.*, 2009, Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up, *Eur. Heart J.* 30, 1598–1606.
- Brunner, F., Brás-Silva, C., Cerdeira, A.S., Leite-Moreira, A.F., 2006, Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis, *Pharmacol. Ther.* 111, 508–531.
- Chackerian, A.A., Oldham, E.R., Murphy, E.E., Schmitz, J., Pflanz, S., Kastelein, R.A., 2007, IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor Complex, *J. Immunol.* 179, 2551–2555.
- Clark, A.L., Cleland, J.G., 2000, The control of adrenergic function in heart failure: therapeutic intervention, *Heart Fail. Rev.* 5, 101–114.
- Coglianesi, E.E., Larson, M.G., Vasan, R.S., Ho, J.E., Ghorbani, A., McCabe, E.L., *et al.*, 2012, Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study, *Clin. Chem.* 58, 1673–1681.
- Demyanets, S., Kaun, C., Pentz, R., Krychtiuk, K.A., Rauscher, S., Pfaffenberger, S., *et al.*, 2013, Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature, *J. Mol. Cell. Cardiol.* 60, 16–26.
- Demyanets, S., Speidl, W.S., Tentzeris, I., Jarai, R., Katsaros, K.M., Farhan, S., *et al.*, 2014, Soluble ST2 and interleukin-33 levels in coronary artery disease: Relation to disease activity and adverse outcome, *PLoS One* 9.
- Dhillon, O.S., Narayan, H.K., Khan, S.Q., Kelly, D., Quinn, P.A., Squire, I.B., *et al.*, 2013, Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?, *Int. J. Cardiol.* 167, 2182–2188.

- Dieplinger, B., Egger, M., Poelz, W., Gabriel, C., Haltmayer, M., Mueller, T., 2011, Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females, *Clin. Chem. Lab. Med.* 49, 1515–1518.
- Dieplinger, B., Januzzi, J.L., Steinmair, M., Gabriel, C., Poelz, W., Haltmayer, M., *et al.*, 2009, Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - The Presage™ ST2 assay, *Clin. Chim. Acta* 409, 33–40.
- Dietz, W.H., 2000, Thrombolytic therapy in the elderly, *Lancet* 356, 2028–2030.
- Dinareello, C.A., 2009, Immunological and Inflammatory Functions of the Interleukin-1 Family, *Annu. Rev. Immunol.* 27, 519–550.
- Farcaş, A.D., Anton, F.P., Goidescu, C.M., Gavrilă, I.L., Vida-Simiti, L.A., Stoia, M.A., 2017, Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients, *Dis. Markers* 2017.
- Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients, *Lancet* 343, 311–322.
- Foryst-Ludwig, A., Hartge, M., Clemenz, M., Sprang, C., Heß, K., Marx, N., *et al.*, 2010, PPARγ activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice, *Cardiovasc. Diabetol.* 9, 1–9.
- Fousteris, E., Panoutsopoulos, G., Theodosis-Georgilas, A., Hantanis, S., Tzerefos, S., Matsagos, S., *et al.*, 2011, Type 2 Diabetes Is Connected With Higher Soluble St2 Levels, Even Higher When Left Ventricular Diastolic Dysfunction Is Present, *Eur. J. Intern. Med.* 22, Supple, S32-.
- Gadina, M., Jefferies, C.A., 2007, IL-33: a sheep in wolf's clothing?, *Sci. STKE* 2007, 31–34.
- Haddad, P., Cole, D.E.C., Bailo, B.G., 2010, Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention, *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2010:3 173–186
- Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., Küchler, A.M., 2009, Interleukin-33 - cytokine of dual function or novel alarmin? *Trends Immunol.* 30, 227–233.
- Hartopo, A. B., Setianto, B. Y., Pradana, A. D., Murti, H., Hadwiono, M.R., 2016, *Pengaruh Kadar Soluble ST2 Serum Terhadap Risiko Kejadian Kardiovaskular Mayor Selama Perawatan Intensif Pada Infark Miokard Akut Dengan Elevasi Segment ST*, Fakultas Kedokteran Universitas Gajah Mada.

- Hartopo, A.B., Sukmasari, I., Puspitawati, I., 2018, The Utility of Point of Care Test for Soluble ST2 in Predicting Adverse Cardiac Events during Acute Care of ST-Segment Elevation Myocardial Infarction. *Hindawi* 2018, 9.
- Hayakawa, H., Hayakawa, M., Kume, A., Tominaga, S.I., 2007, Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. *J. Biol. Chem.* 282, 26369–26380.
- Ho, J.E., Larson, M.G., Ghorbani, A., Cheng, S., Vasani, R.S., Wang, T.J., *et al.*, 2013, Soluble ST2 predicts elevated SBP in the community. *J. Hypertens.* 31, 1431–1436.
- Ho, J.E., Sritara, P., Defilippi, C.R., Wang, T.J., 2015, Soluble ST2 testing in the general population. *Am. J. Cardiol.* 115, 22B–25B.
- Huang, H., 2004, Cell mechanics and mechanotransduction: pathways, probes, and physiology. *AJP Cell Physiol.* 287, C1–C11.
- Huang, W.P., Zheng, X., He, L., Su, X., Liu, C.W., Wu, M.X., 2018, Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction. *Chin. Med. J. (Engl.)* 131, 1282–1288.
- Hutomo, P., Hartopo, A.B., Sukmasari, I., 2017, *Prognostic Factor of Soluble ST2 Serum on 90 Days-Major Cardiovascular Events in ST-Elevation Acute Myocardial Infarction Patients with Reperfusion Therapy* 3, 1–13, Fakultas Kedokteran Universitas Gajah Mada.
- Ibanez, B., Arslan, F., Bongartz, L., ten Berg, J.M., Jukema, J.W., *et al.*, 2018, 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. *Netherlands Hear. J.* 26, 417–421.
- Ieda, M., Tsuchihashi, T., Ivey, K.N., Ross, R.S., Hong, T.T., Shaw, R.M., *et al.*, 2009, Cardiac Fibroblasts Regulate Myocardial Proliferation through  $\beta$ 1 Integrin Signaling. *Dev. Cell* 16, 233–244.
- Irmalita, Tobing, D.P., Juzar, D.A., Firdaus, I., Danny, S.S., Widyantoro, B., Rossimarina, V., *et al.*, 2018, *Pedoman Tata Laksana Sindrom Koroner Akut Edisi Keempat. Perhimpun. Dr. Spes. Kardiovask. Indones.*, Jurnal Kardiologi Indonesia, Jakarta
- Iwahana, H., Hayakawa, M., Kuroiwa, K., Tago, K., Yanagisawa, K., Noji, S., *et al.*, 2004, Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. *Biochim. Biophys. Acta - Gene Struct. Expr.* 1681, 1–14.
- Januzzi, J.L., 2013, ST2 as a cardiovascular risk biomarker: From the bench to the bedside. *J. Cardiovasc. Transl. Res.* 6, 493–500.

- Januzzi, J.L., Butler, J., Jarolim, P., Sattar, N., Vijapurkar, U., Desai, M., *et al*, 2017, Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. *J. Am. Coll. Cardiol.* 70, 704–712.
- Jenkins, W.S., Roger, V.L., Jaffe, A.S., Weston, S.A., AbouEzzeddine, O.F., Jiang, R., *et al.*, 2017, Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. *Am. J. Med.* 130, 1112.e9-1112.e15.
- Kakkar, R., Lee, R.T., 2010, Intramyocardial fibroblast myocyte communication. *Circ. Res.* 106, 47–57.
- Kakkar, R., Lee, R.T., 2008, The IL-33/ST2 pathway: Therapeutic target and novel biomarker. *Nat. Rev. Drug Discov.* 7, 827–840.
- Knöll, R., Hoshijima, M., Hoffman, H.M., Person, V., Lorenzen-Schmidt, I., Bang, M.L., *et al.*, 2002, The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. *Cell* 111, 943–955.
- Krumm, B., Xiang, Y., Deng, J., 2014, Structural biology of the IL-1 superfamily: Key cytokines in the regulation of immune and inflammatory responses. *Protein Sci.* 23, 526–538.
- Küchler, A.M., Pollheimer, J., Balogh, J., Sponheim, J., Manley, L., Sorensen, D.R., *et al.*, 2008, Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. *Am. J. Pathol.* 173, 1229–1242.
- Kumar, V., Abbas, A.K., Aster, J.C., 2013. *Robbins Basic Pathology*, 9th Edition, Elsevier, Philadelphia.
- Lax, A., Sanchez-Mas, J., Asensio-Lopez, M.C., Fernandez-Del Palacio, M.J., Caballero, L., Garrido, I.P., *et al.*, 2015, Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. *JACC Hear. Fail.* 3, 50–58.
- Lécart, S., Lecointe, N., Subramaniam, A., Alkan, S., Ni, D., Chen, R., *et al.*, 2002, Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. *Eur. J. Immunol.* 32, 2979–2987.
- Lee, C.S., Tkacs, N.C., 2008, Current Concepts of Neurohormonal Activation in Heart Failure. *AACN Adv. Crit. Care* 19, 364–385.
- Li, H., Tago, K., Io, K., Kuroiwa, K., Arai, T., Iwahana, H., *et al.*, 2000, The cloning and nucleotide sequence of human ST2L cDNA. *Genomics* 67, 284–290.
- Liew, F.Y., Girard, J.P., Turnquist, H.R., 2016, Interleukin-33 in health and disease. *Nat. Rev. Immunol.* 16, 676–689.
- Lilly, L.S., 2016. *Pathophysiology of Heart Disease*, 6th Edition, Wolters Kluwer,

### Philadelphia

- Liu, X., Hu, Y., Huang, W., Zhang, G., Cao, S., Yan, X., *et al.*, 2018, Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI. *Int. Heart J.* 1–8.
- Lüthi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan, C., *et al.*, 2009, Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases. *Immunity* 31, 84–98.
- Marino, R., Magrini, L., Orsini, F., Russo, V., Cardelli, P., Salerno, G., *et al.*, 2017, Comparison between soluble ST2 and high-sensitivity troponin I in predicting short-term mortality for patients presenting to the Emergency Department with chest pain. *Ann. Lab. Med.* 37, 137–146.
- Miller, A.M., 2011, Role of IL-33 in inflammation and disease. *J. Inflamm.* 8, 22.
- Miller, A.M., Purves, D., McConnachie, A., Asquith, D.L., Batty, G.D., Burns, H., *et al.*, 2012, Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes? *PLoS One* 7, 1–7.
- Miñana, G., Núñez, J., Bayés-Genís, A., Revuelta-López, E., Ríos-Navarro, C., Núñez, E., *et al.*, 2018, ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. *Int. J. Cardiol.* 270, 336–342.
- Mueller, T., Dieplinger, B., 2013, The presage@ST2 assay: Analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. *Expert Rev. Mol. Diagn.* 13, 13–30.
- Mueller, T., Zimmermann, M., Dieplinger, B., Ankersmit, H.J., Haltmayer, M., 2012, Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: The MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. *Clin. Chim. Acta* 413, 1493–1494.
- Mukau, L., 2011, A Critical Appraisal of the Evolution of ST Elevation Myocardial Infarction ( STEMI ) Therapy and the Evidence Behind the Current Treatment Guidelines. *Am. J. Clin. Med.* @BULLET Winter 15–36.
- Noriega, F.J., Vives-Borrás, M., Solé-González, E., García-Picart, J., Arzamendi, D., Cincá, J., 2014, Influence of the extent of coronary atherosclerotic disease on ST-segment changes induced by ST elevation myocardial infarction. *Am. J. Cardiol.* 113, 757–764.
- O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., *et al.*, 2013, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 127, e362–e425.

- O'Neill, L.A.J., 2008, The interleukin-1 receptor/Toll-like receptor superfamily: 10 Years of progress. *Immunol. Rev.* 226, 10–18.
- Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., *et al.*, 2010, IL-33 is a crucial amplifier of innate rather than acquired immunity. *Proc. Natl. Acad. Sci.* 107, 18581–18586.
- Onda, H., Kasuya, H., Takakura, K., Hori, T., Imaizumi, T., Takeuchi, T., *et al.*, 1999. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. *J. Cereb. Blood Flow Metab.* 19, 1279–88.
- Opie, L.H., Commerford, P.J., Gersh, B.J., Pfeffer, M.A., 2006, Controversies in ventricular remodelling. *Lancet* 367, 356–367.
- Palmer, G., Lipsky, B.P., Smithgall, M.D., Meininger, D., Siu, S., Talabot-Ayer, D., *et al.*, 2008, The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. *Cytokine* 42, 358–364.
- Pascual-Figal, D.A., Januzzi, J.L., 2015. The biology of ST2: The international ST2 consensus panel. *Am. J. Cardiol.* 115, 3B–7B.
- Pascual-Figal, D.A., Ordoñez-Llanos, J., Tornel, P.L., Vázquez, R., Puig, T., Valdés, M., *et al.*, 2009, Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. *J. Am. Coll. Cardiol.* 54, 2174–2179.
- Pfeiler, S., Winkels, H., Kelm, M., Gerdes, N., 2017, IL-1 family cytokines in cardiovascular disease. *Cytokine* 0–1.
- Pinkerman, C., Sander, P., Breeding, J.E., Brink, D., Curtis, R., 2013. Heart Failure in Adults. *Inst. Clin. Syst. Improv.* 19, S108.
- Pinto, D.S., Frederick, P.D., Chakrabarti, A.K., Kirtane, A.J., Ullman, E., Dejam, A., *et al.*, 2011, Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation* 124, 2512–2521.
- Planavila, A., Fernández-Solà, J., Villarroya, F., 2017, Cardiokines as Modulators of Stress-Induced Cardiac Disorders. *Adv. Protein Chem. Struct. Biol.* 108, 227–256.
- Rehman, S.U., Mueller, T., Januzzi, J.L., 2008, Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. *J. Am. Coll. Cardiol.* 52, 1458–1465.
- Richards, A.M., Di Somma, S., Mueller, T., 2015, ST2 in stable and unstable ischemic heart diseases. *Am. J. Cardiol.* 115, 48B–58B.
- Riskesdas, 2013, Hasil Riskesdas 2013, Kemenkes RI.

- Sabatine, M.S., Morrow, D.A., Higgins, L.J., MacGillivray, C., Guo, W., Bode, C., *et al.*, 2008, Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction, *Circulation* 117, 1936–1944.
- Sadoshima, J. ichi, Xu, Y., Slayter, H.S., Izumo, S., 1993, Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro, *Cell* 75, 977–984.
- Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N.J., Lee, R.T., 2007, IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system, *J. Clin. Invest.* 117, 1538–1549.
- Schmieder, A., Multhoff, G., Radons, J., 2012, Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells, *Cytokine* 60, 514–521.
- Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., *et al.*, 2005, IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines, *Immunity* 23, 479–490.
- Seki, K., Sanada, S., Kudinova, A.Y., Steinhauser, M.L., Handa, V., Gannon, J., *et al.*, 2009, Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. *Circ. Hear. Fail.* 2, 684–691.
- Shimpo, M., Morrow, D., Weinberg, E., Sabatine, M., Murphy, S., Antman, E., *et al.*, 2004, Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction. *Circulation* 109, 2186–90.
- Sims, J.E., Pan, Y., Smith, D.E., Nicklin, M.J.H., Barton, J.L., Bazan, J.F., *et al.*, 2001, A new nomenclature for IL-1-family genes, *Trends Immunol.* 22, 536–537.
- Skyschally, A., Schulz, R., Heusch, G., 2008, Pathophysiology of myocardial infarction. Protection by ischemic pre- and postconditioning. *Herz* 33, 88–100.
- Sundlisæter, E., Edelmann, R.J., Hol, J., Sponheim, J., Kchler, A.M., Weiss, M., Udalova, I.A., *et al.*, 2012, The alarmin IL-33 is a notch target in quiescent endothelial cells. *Am. J. Pathol.* 181, 1099–1111.
- Tavi, P., Laine, M., Weckström, M., Ruskoaho, H., 2001, Cardiac mechanotransduction: From sensing to disease and treatment. *Trends Pharmacol. Sci.* 22, 254–260.
- Tominaga, S.I., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Komatsu, N., 1999, Presence and Expression of a Novel Variant Form of ST2 Gene Product in Human Leukemic Cell Line UT-7GM. *Biochem Biophys Res Commun* 264, 14–18.

- Wang, Y., Zhou, Q., An, T., Zhang, R., Huang, Y., Gan, T., *et al.*, 2015, Reference value and clinical correlates of soluble ST2 in healthy community-based Chinese population, *Zhonghua Xin Xue Guan Bing Za Zhi* 43, 900–903.
- Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., MacGillivray, C., Tominaga, S. ichi, Solomon, S.D., *et al.*, 2002, Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. *Circulation* 106, 2961–2966.
- Weinberg, E.O., Shimpo, M., Hurwitz, S., Tominaga, S. ichi, Rouleau, J.L., Lee, R.T., 2003, Identification of serum soluble ST2 receptor as a novel heart failure biomarker. *Circulation* 107, 721–726.
- Weir, R.A.P., Miller, A.M., Murphy, G.E.J., Clements, S., Steedman, T., Connell, J.M.C., *et al.*, 2010, Serum Soluble ST2. A Potential Novel Mediator in Left Ventricular and Infarct Remodeling After Acute Myocardial Infarction. *J. Am. Coll. Cardiol.* 55, 243–250.
- World Health Organization (WHO), 2011. Fact Sheet Top 10 Leading Causes of Death 1–5. [https://doi.org/AnnAfrMed\\_2009\\_8\\_3\\_147\\_57236](https://doi.org/AnnAfrMed_2009_8_3_147_57236) [pii] 10.4103/1596-3519.57236
- Xu, Y., Tao, X., Shen, B., Horng, T., Medzhitov, R., Manley, J.L., *et al.*, 2000, Structural basis for signal transduction by the toll/interleukin-1 receptor domains. *Nature* 408, 111–115.
- Yamamoto, K., Dang, Q.N., Kennedy, S.P., Osathanondh, R., Kelly, R.A., Lee, R.T., 1999, Induction of Tenascin-C in Cardiac Myocytes by Mechanical Deformation. *J. Biol. Chem.* 274, 21840–21846.
- Yndestad, A., Marshall, A.K., Hodgkinson, J.D., Tham, E.L., Sugden, P.H., Clerk, A., 2010, Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. *Int. J. Biochem. Cell Biol.* 42, 263–272.
- Yu, J., Oh, P.C., Kim, M., Moon, J., Park, Y.M., Lee, K., *et al.*, 2017, Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP 2, *PLOS One*, 1–12.
- Zhao, W.-H., Hu, Z.-Q., 2012, Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. *Cytokine* 58, 267–273.